Palantir Technologies finds itself at a critical juncture, navigating a storm of political controversy while preparing to report financial results that are expected to showcase blistering growth. The data analytics firm will release its first-quarter 2026 figures after the U.S. market closes on May 4, a moment that will test investor conviction in its premium-priced stock.
The upcoming report is forecast to be robust. Consensus estimates, largely aligned with management’s own guidance, project revenue of $1.54 billion. This would represent a year-over-year surge of 74%. Analysts also anticipate normalized earnings per share of $0.28, with operating income expected to reach approximately $872 million.
This operational strength is built on a dual foundation. Government contracts remain a cornerstone, with the U.S. Department of Defense’s “Maven Smart System” now an official program, securing long-term revenue streams. Simultaneously, the commercial sector is exploding. U.S. commercial revenue skyrocketed 137% in the final quarter of 2025, and management aims to more than double this segment to surpass $3 billion for the full 2026 fiscal year, which is projected to grow 61% overall.
Recent contract wins bolster this outlook. On April 22, the U.S. Department of Agriculture signed a framework agreement worth $300 million to modernize supply chains. Technologically, Palantir has integrated xAI’s “Grok 4.20” models into its Artificial Intelligence Platform (AIP) since April, enhancing its product suite.
However, this formidable business momentum is colliding with a significant political backlash. On April 21, the company released a summary of CEO Alex Karp’s forthcoming book, “The Technological Republic.” In it, Karp advocates for a radical overhaul of Western defense policy, including a U.S. draft and an accelerated AI arms race, positioning Palantir’s software as essential infrastructure for state power.
Should investors sell immediately? Or is it worth buying Palantir?
The manifesto has sparked intense criticism, particularly in the United Kingdom. Parliamentarians there recently labeled the vision “dystopian,” prompting calls for a review of Palantir’s existing contracts with the UK’s National Health Service and Ministry of Defence. This controversy introduces a new layer of risk regarding the stability of its international government partnerships.
Financially, the company’s profitability is not in doubt. The adjusted operating margin hit a record 57.4% in Q4 2025, while the GAAP profit margin stood at a strong 41%. Yet, the stock’s valuation presents the largest hurdle for investors. Shares currently trade at a price-to-earnings ratio of 111 based on forward estimates, with a price-to-sales multiple of 85—the highest among major software providers.
This rich valuation has coincided with insider selling, with management offloading shares worth nearly $433 million over the past three months. The equity has been volatile, currently trading at €129.08. While it has recovered over seven percent on a weekly basis, pushing it above the 50-day moving average of €123.11, it remains almost 30% below its November peak and is down roughly ten percent year-to-date.
Wall Street remains divided. Morgan Stanley sees potential for raised annual guidance and maintains a $205 price target. Conversely, Mizuho recently trimmed its target to $185, citing fluctuating demand in cybersecurity. The upcoming earnings webcast will be scrutinized not just for financial performance, but for management’s commentary on mitigating political fallout. To justify its extreme market premium, Palantir will need to decisively exceed high expectations on May 4.
Ad
Palantir Stock: Buy or Sell?! New Palantir Analysis from April 23 delivers the answer:
The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 23.
Palantir: Buy or sell? Read more here...









